CA Patent

CA2561839A1 — Multi-phase contraceptive preparation based on a natural estrogen

Assigned to Bayer Intellectual Property GmbH · Expires 2005-11-03 · 21y expired

What this patent protects

The invention relates to a multi-phase contraceptive preparation that is bas ed on a natural estrogen combined with a synthetic gestagen. Conventional anovulant preparations known in the prior art have proven to be reliable and safe in large-scale application. The aim of the inve…

USPTO Abstract

The invention relates to a multi-phase contraceptive preparation that is bas ed on a natural estrogen combined with a synthetic gestagen. Conventional anovulant preparations known in the prior art have proven to be reliable and safe in large-scale application. The aim of the invention is to provide a preparation that offers a higher contraceptive safety over the entire durati on of the cycle, improves the cyclic bleeding behavior, and reduces or excludes side-effects, such as tender breasts, headaches, depressive moods, and libid o disorders and the like.

Drugs covered by this patent

Patent Metadata

Patent number
CA2561839A1
Jurisdiction
CA
Classification
—
Expires
2005-11-03
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Intellectual Property GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.